NO

NovMetaPharma Co., Ltd.

Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.

229500 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
서울특별시 강남구 언주로 727 13층 (논현동, 트리스빌딩), 강남구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

NovMetaPharma Co., Ltd. is a biopharmaceutical company specializing in the research, development, and commercialization of first-in-class drugs for metabolic and fibrotic diseases. The company focuses on creating novel treatments with differentiated mechanisms to address significant unmet medical needs. Its core pipeline includes therapeutic candidates for conditions such as type 2 diabetes, obesity, chronic kidney disease, and fibrosis, with lead assets including Cyclo-Z and CHP. In addition to its primary focus on drug development, the company also develops health supplements and sells related raw materials.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for NovMetaPharma Co., Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all NovMetaPharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for NovMetaPharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Pluri Inc. Logo
Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.
Israel PLUR
A global supplier of generic APIs using AI to accelerate drug development.
South Korea 041910
Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland PPGN
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea 335810
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea 334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore 950210
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea 296160
PROTEINA CO.,LTD. Logo
A biotech firm specializing in proteomics for drug discovery and diagnostics in oncology.
South Korea 468530
PROTIA INC. Logo
Develops IVD kits and instruments for allergy, POCT, infectious & autoimmune diseases.
South Korea 303360

Talk to a Data Expert

Have a question? We'll get back to you promptly.